SKLB-23bb is an orally bioavailable HDAC6-selective inhibitor and also has microtubule-disrupting ability.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 198 | |
4 mg | In stock | $ 356 | |
8 mg | In stock | $ 601 | |
20 mg | In stock | $ 1099 | |
40 mg | In stock | $ 1736 |
Description | SKLB-23bb is an orally bioavailable HDAC6-selective inhibitor and also has microtubule-disrupting ability. |
Targets&IC50 | HDAC6:17 nM |
In vivo | In vivo efficacy evaluations of colorectal HCT116, acute myelocytic leukemia MV4-11, and B cell lymphoma Romas xenografts, SKLB-23bb more effectively inhibited the tumor growth than SAHA even at a 4-fold reduced dose or ACY-1215 at the same dose. SKLB-23bb is a potent oral anticancer candidate for selective HDAC6 inhibitor. |
CAS No. | 1815580-06-3 |
Chemical Formula | C21H24N4O4 |
Molecular Weight | 396.447 |
Solubility | DMSO: 32 mg/mL (80.72 mM) |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom